Lab-Grown Diamond Resale Value, the Honest 2026 Position

The buyback offers coming out of major retailers for lab-grown diamonds right now sit at 15 to 30 percent of original purchase price. Not 50. Not the number you'd hope for after spending $3,000 on a stone. Fifteen to thirty cents on the dollar.

If you're coming to this without the broader pricing context, our analysis of the 86 percent spread between lab and natural prices covers the purchase side in depth. This post is specifically about what happens on the other end, when you want to sell.

Why the secondary market is so thin

Three things are driving the poor resale position for lab-grown diamonds, and they're all structural rather than temporary.

The first is supply. Lab-grown production has accelerated dramatically over the past four years, driven by falling synthesis costs. Retailers don't need your used one carat stone because they can source a new one at lower wholesale than they could two years ago. There's no incentive to pay you a meaningful buyback rate when fresh supply is abundant and cheap.

The second is consumer expectation. Lab-grown diamonds have been marketed so effectively as the "affordable option" that buyers in the secondary market won't pay natural-adjacent prices for them. The category has been framed as value for money rather than intrinsically scarce, which is fine for the purchase experience but terrible for resale demand.

The third is the absence of a functioning peer to peer market. Natural diamonds have decades of established secondary market infrastructure: auction houses, estate dealers, dedicated resellers. Lab-grown has eBay listings and not much else. When the only serious buyers are retailers running their own buyback programmes, price discovery is entirely on their terms.

The buyback numbers, plainly

Based on current buyback programmes at major retailers, here is where the two categories sit on a like-for-like 1ct G VS2 round:

Category	Typical buyback rate	What that means on a $3,500 purchase
Lab-grown diamond	15 to 30% of purchase price	$525 to $1,050 returned
Natural diamond	40 to 60% of purchase price	$1,400 to $2,100 returned

The gap is real. On a mid-range stone, you're looking at a difference of roughly $900 to $1,000 in what you'd recover. That's not nothing.

But before that number sends you into a panic, read the next section.

The maths that make this less alarming

The resale gap looks bad until you factor in what you paid in the first place.

Our cross-retailer index currently shows lab-grown diamonds trading at discounts of 79 to 90 percent versus natural equivalents, depending on shape. A round lab-grown sits at $342 per carat versus $2,006 per carat for a comparable natural round. An emerald cut lab is $385 versus $2,013. Baguettes are running at a 90 percent discount, the widest we currently track.

Shape	Natural $/ct	Lab $/ct	Lab discount
Round	$2,006	$342	83.0%
Oval	$2,331	$409	82.5%
Emerald	$2,013	$385	80.9%
Cushion	$2,714	$468	82.8%
Radiant	$2,639	$468	82.3%
Pear	$1,999	$410	79.5%
Asscher	$2,297	$471	79.5%
Marquise	$2,090	$447	78.6%
Princess	$2,021	$401	80.2%
Heart	$2,078	$385	81.5%
Baguette	$2,896	$289	90.0%
Trillion	$3,490	$466	86.6%

Run the scenario for a 1ct G VS2 round. A comparable natural stone might cost $5,000 retail. The lab-grown equivalent might cost $900. Sell the natural after three years and recover 50 percent: you get $2,500 back. Sell the lab-grown and recover 25 percent: you get $225 back. The natural wins on resale by $2,275.

But you paid $4,100 less upfront for the lab-grown stone. The resale disadvantage doesn't erase the purchase savings. Not even close.

This is the framework most resale conversations miss. Lab-grown diamonds are not a bad financial decision because they depreciate faster. They're a bad investment vehicle, full stop. But so are natural diamonds for most buyers. The question isn't "which one holds value better?" It's "which one gives me more diamond for my money right now?"

What labs are not, and what they are

Lab-grown diamonds are not an investment. Anyone who bought one in 2020 expecting the kind of value retention that coloured gemstones or rare natural diamonds can sometimes produce has learned this the hard way. Production costs keep falling. Wholesale prices follow. Retail prices follow wholesale. Resale prices follow retail, and right now they're following it down.

That's not a flaw in the product. Lab-grown diamonds are chemically, optically, and physically identical to natural diamonds. They're spectacular at being diamonds. They're just not scarce, and scarcity is what drives resale value in the luxury goods market.

If you want a diamond that might hold reasonable value, buy a natural. If you want the largest, best-quality diamond your budget allows and you're not planning to resell, buy lab-grown and spend the money saved on the setting, or a holiday, or anything else.

The price trajectory for lab-grown stones over the last two years has been consistently downward. That's good news for buyers and bad news for anyone holding existing stock. It's also why the resale problem is unlikely to improve any time soon.

Shapes where the gap hurts most

Not all shapes carry equal resale exposure.

Baguettes and trillions are running the widest discounts versus natural of any shape we track, at 90 and 86.6 percent respectively. If you purchased a lab-grown baguette at a time when the discount was narrower, you're carrying more downside than someone who bought a round or a marquise. The secondary market for those shapes is niche even for natural stones, which means lab-grown versions have almost no organic buyer pool.

Rounds and ovals are the most liquid shapes in natural diamonds. They're not dramatically more liquid in lab-grown, but the volume is significant: over two million active round listings and over one million ovals in our current index. There's at least some market activity to anchor pricing conversations.

Marquise is worth watching. At a 78.6 percent discount to natural, it's the narrowest spread in our dataset. That's partly a function of the shape's current popularity in fine jewellery. Whether that popularity translates into meaningfully better resale for lab-grown marquise stones is genuinely unclear. The secondary market hasn't been tested at scale yet.

The retailer buyback game

Most major retailers offer some form of buyback or trade in programme, but the terms vary significantly and the headline numbers can mislead.

Trade in credit applied toward a new purchase is almost always more generous than a straight cash buyback. Retailers can afford to offer 40 to 50 percent trade in credit on a lab-grown diamond if they're also capturing a new sale at full margin. The cash equivalent for the same stone might be 15 to 20 percent.

Read the upgrade policy fine print. Some retailers lock trade in credit to stones of equal or greater value, which sounds reasonable until you discover that "equal or greater" is calculated at current retail prices. Since retail prices for lab-grown have been falling, your 2021 stone might not qualify as an upgrade vehicle toward a 2026 stone because the newer version retails for less.

If you're selling outright, peer to peer platforms typically return more than retailer buyback programmes, but the market is thin and you'll wait. For lab-grown diamonds specifically, patience is often rewarded with disappointment. Buyers on those platforms know the retail price of a comparable new stone and offer accordingly.

Who should buy lab-grown

Most buyers. That's the honest answer.

If your budget is $5,000 and you want the most impressive diamond you can put in front of someone, a lab-grown is almost certainly the right call. The 79 to 90 percent purchase discount more than prices in the resale gap. You're spending a fraction of what a natural would cost, and even a poor resale rate leaves you ahead on total outlay.

If you're buying an engagement ring with sentimental weight and you want something that holds its value across generations, the calculus shifts toward natural. Not because natural diamonds are a great investment (they're mostly not) but because the secondary market infrastructure is more established and the resale path is genuinely better.

If you're buying for pure aesthetic pleasure with no financial considerations, buy whichever one you find more beautiful.

The mistake is treating lab-grown as a category that should perform like natural on the secondary market. It doesn't, it won't, and the structural reasons aren't going away.

What we're watching

Production costs for lab-grown diamonds haven't bottomed out. The manufacturing base that supplies much of global wholesale continues to scale. If wholesale prices drop another 20 to 30 percent over the next 18 months (and there's no obvious reason they won't), retail follows, and today's buyback offers look even worse relative to what a buyer could pay for a new stone.

The shape that interests us most right now is marquise. At 78.6 percent, it's running the narrowest discount versus natural of any shape in our index. If consumer appetite for marquise cuts keeps growing, it may decouple slightly from the broader lab-grown pricing trend. We're not predicting that. We're watching it.

For anyone currently holding a lab-grown diamond and considering selling: get multiple quotes, prefer trade in credit over cash if you're planning to buy again, and don't benchmark against what natural diamonds recover. Different category, different economics. The sooner those mental models are kept separate, the clearer the conversation with a retailer becomes.